AUTHORS
Elena Tarabra, PhD, Jude Fry2, Tauseefullah Akhund3, Peng Liu4, Ajay K. Singh5, Meera Ramanujam6, Christopher Dvorak, MD7, Cory Williams, MBBS, DPhil8, Tobin J Cammett9
AFFILIATIONS
1 Alexion, AstraZeneca Rare Disease, New Haven, Connecticut, United States
2 Alexion Pharma GmbH, AstraZeneca Rare Disease, Baar, Switzerland
3 Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, United States
4 Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, United States
5 Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, United States
6 Alexion, AstraZeneca Rare Disease, New Haven, Connecticut, United States
7 University of California San Francisco, San Francisco, California, United States
8 Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, United States
9 Alexion, AstraZeneca Rare Disease, New Haven, Connecticut, United States
ABSTRACT
Introduction: Hematopoietic stem cell transplantation–associated thrombotic microangiopathy (HSCT-TMA) is a life-threatening complication of HSCT, in which endothelial dysfunction and terminal complement activation are central to the pathophysiology. Disease progression can lead to multi-organ dysfunction, including renal injury resulting in proteinuria. Ravulizumab (rav), a long-acting terminal complement C5 inhibitor, was evaluated in a prospective trial in children with HSCT-TMA which resulted in meaningful overall survival of 87.2% at 26 weeks (wks). Exploratory biomarker analyses for pathways dysregulated in HSCT-TMA were performed, including urinary complement factors Ba and sC5b-9 (markers of localized renal complement activation), plasma complement C5a (proinflammatory protein marker of terminal complement activation), and plasma VCAM-1 (marker of endothelial cell activation and injury). Assessments included baseline (BL) levels, change from baseline (CFB) with rav treatment, and associations with TMA response in children with HSCT-TMA.
Methods: A phase 3, open-label, single-arm trial (NCT04557735) was conducted in children (age ≥28 d to <18 y) who developed HSCT-TMA. Participants (pts) received best supportive care (BSC) and weight-based intravenous rav for 26 wks, followed by 26 wks of only BSC. Plasma and spot urine samples for biomarker analyses were collected at BL and pre-dose through 26 wks, processed, and stored at < -70°C until tested. Ligand-binding assays, validated to 2018 FDA guidance, were used for quantitation and spot urine biomarker levels were corrected for void volume by normalizing to matched urine creatinine (Cr). Reference ranges of biomarker levels (ULN) were established using a receiver-operator curve analysis from a prospectively collected cohort of pediatric healthy donors. Pts were evaluated for complete (all components met) or partial (1-2 components met) TMA response during the 26-wk treatment period based on three components: renal response (≥50% reduction in urine protein/creatinine ratio); platelet response (≥50% increase in platelets); and lactate dehydrogenase response (normalization with absence of schistocytes).
Results: 41 pts were enrolled, with a median (range) age of 6.0 (<1 to 17) years. At BL, urinary sC5b-9/Cr levels were elevated (>2.53 ng/mg Cr) in 100% of evaluable pts (n=29; median=97 ng/mg Cr). At wk 26, levels decreased with rav treatment (n=19; median=1.31 ng/mg Cr), representing a −98.7% CFB. Among 22 pts who achieved post-BL urinary sC5b-9 normalization anytime through wk 26, 19 (86%) achieved ≥1 TMA response, with 15 (68%) achieving renal response.
At BL, urinary factor Ba/Cr levels were elevated (>55.42 ng/mg Cr) in 100% of evaluable pts (n=29; median=2249 ng/mg Cr). At wk 26, levels decreased with rav treatment (n=20; median=783 ng/mg Cr), representing a −72.5% CFB. Among 8 pts who achieved post-BL urinary factor Ba/Cr normalization anytime through wk 26, 100% achieved ≥1 TMA response, with 7 (88%) achieving renal response.
At BL, plasma C5a levels were elevated (>5.77 ng/ml) in 62% of evaluable pts (n=34; median=7.50 ng/ml). At wk 26, levels decreased with rav treatment (n=19; median=4.36 ng/ml), representing a −32.0% CFB. Among 21 pts who achieved post-BL plasma C5a normalization anytime through wk 26, 19 (86%) achieved ≥1 TMA response, with 13 (62%) achieving renal response.
At BL, plasma VCAM-1 levels were elevated (>905 ng/ml) in 77% of evaluable pts (n=35; median=2125 ng/ml). At wk 26, levels decreased with rav treatment (n=26; median=1140 ng/ml), representing a −38.1% CFB. Among 15 pts who achieved post-BL plasma VCAM-1 normalization anytime through wk 26, 13 (87%) achieved ≥1 TMA response, with 12 (80%) achieving renal response.
Conclusions: Baseline elevations in complement biomarkers (C5a, sC5b-9 and Ba) and endothelial damage marker VCAM-1 underscore the importance of these key elements to the pathophysiology of HSCT-TMA. Rav treatment reduced levels of these biomarkers through 26 wks and normalization was associated with achievement of at least a partial TMA response, supporting clinically meaningful and beneficial effects of terminal complement inhibition with ravulizumab in pediatric patients with this condition.
DISCLOSURES
Elena Tarabra, PhD: Alexion, AstraZeneca Rare Disease - Current Employment